MedTrace Logo

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00435448 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2009-04-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.

Conditions

  • Benign Prostatic Hyperplasia
  • Enlarged Prostate

Interventions

DRUG

Lonidamine

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • Threshold Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Peter Alken, MD · Fakultät für Klinische Medizin Mannheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • Germany
  • Hungary
  • Italy
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00435448 on ClinicalTrials.gov